It's a tough time for the job market. Amid wider economic uncertainty, some analysts have said that businesses are at a ...

China's Innovent Biologics saidon Monday its GLP-1 injection led to more weight loss and better control of blood sugar in ...

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are ...

Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be ...

Despite all that, there are some good reasons to consider buying into Novo Nordisk -- and the best is its low valuation, given its growth potential. The stock's recent price-to-earnings (P/E) ratio of ...

Novo Nordisk today announced plans to present 11 abstracts at the 76th Annual American Association for the Study of Liver ...

Sure, Eli Lilly’s Tirzepatide-based drugs have caught up significantly to Novo Nordisk’s semaglutide-based ones. As a result, ...

Some investors may welcome the Novo Nordisk Foundation’s sweeping moves to accelerate a strategy shift. Yet the speed and ...

Eli Lilly said on Wednesday it is partnering with Walmart to expand access to Lilly's weight-loss drug Zepbound, which will ...

Eli Lilly said on Wednesday it is partnering with Walmart to sell its weight-loss treatment Zepbound at the retailer's ...

If you have a stake in Novo Nordisk, chances are you have been watching the stock’s swoops and dips with a mix of curiosity and nerves. The past few months have been nothing short of dramatic. After ...

The analysts see “meaningful skew to the downside” as around one-third of Roche’s 2030 revenue is at risk from competitors ...